文献速递鼻科

生物制剂治疗慢性鼻窦炎伴鼻息肉的真实世界前瞻性队列研究

Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study.
PubMed 文献 · Rhinology · 2026-01-01

这项比利时多中心前瞻性IV期真实世界研究纳入360例重度慢性鼻窦炎伴鼻息肉患者,分别接受奥马珠单抗、美泊珠单抗或度普利尤单抗治疗。6个月后所有生物制剂均改善鼻息肉评分、嗅觉功能及患者报告结局,51%患者达良好至优异的多域治疗应答,度普利尤单抗组改善幅度数值上更大。

要点

  • 三种获批生物制剂在真实世界中均对重度CRSwNP产生显著临床获益。
  • 6个月时51%患者达良好至优异多域应答,各药继续治疗率74%–92%。
  • 度普利尤单抗组在多域改善上呈现数值上更大的提升。

核心结论

  • 真实世界队列中三种注册生物制剂对重度CRSwNP均提供显著临床获益。
  • 度普利尤单抗治疗患者观察到数值上更大的改善。

研究设计与样本

  • 比利时多中心、前瞻性、真实世界IV期研究,纳入360例重度CRSwNP患者。
  • 患者于2022年3月至2025年4月启动治疗:奥马珠单抗65例、美泊珠单抗242例、度普利尤单抗53例。
  • 基线与6个月后收集临床数据,依据EUFOREA标准评估治疗应答。

主要发现

  • 6个月后各生物制剂组鼻息肉评分、嗅觉功能及患者报告结局均改善,哮喘控制亦同步改善。
  • 51%患者达良好至优异的多域治疗应答。
  • 6个月后继续治疗率:奥马珠单抗74%、美泊珠单抗81%、度普利尤单抗92%。
  • 未报告严重不良事件。

关键数值与推荐

  • 治疗应答依据EUFOREA标准评估。
  • 良好至优异多域治疗应答见于51%患者。
  • 6个月后继续治疗率奥马珠单抗74%、美泊珠单抗81%、度普利尤单抗92%。

临床怎么用

  • 真实世界数据支持三种生物制剂用于重度CRSwNP的临床决策。
  • EUFOREA标准可用于6个月时评估多域治疗应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monoclonal antibody therapies targeting type 2 inflammation for chronic rhinosinusitis with nasal polyps (CRSwNP) have shown efficacy in randomized controlled trials (RCTs), however prospective real-world comparative data across all appro-ved biologics remain limited. We aimed to evaluate the real-world effectiveness of omalizumab, mepolizumab, and dupilumab in patients with severe CRSwNP. METHODOLOGY: A prospective, multicentre, real-world phase IV study in Belgium, enrolling 360 patients with severe CRSwNP initiating treatment with omalizumab (n=65), mepolizumab (n=242), or dupilumab (n=53) between March 2022 and April 2025. Clinical data were collected at baseline and after 6 months. The therapeutic response was evaluated based on EUFOREA criteria. RESULTS: After 6 months, nasal polyp score (NPS), olfactory function, and patient-reported outcomes improved across all biologics, with concurrent improvements in asthma control within each treatment group. A good-to-excellent multidomain therapeutic response was achieved in 51% of patients, and treatment continuation beyond 6 months was observed in 74% of omalizumab-, 81% of mepolizumab-, and 92% of dupilumab-treated patients. No severe adverse events were reported. CONCLUSION: In this real-world cohort, the three registered biologics provided significant clinical benefit in severe CRSwNP, with numerically larger improvements observed in patients treated with dupilumab.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Blauwblomme M, Viskens AS, Bonne E, et al. Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study. Rhinology. 2026. PMID: 41989130. doi:10.4193/Rhin26.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。